Boston Globe -- Boston researchers plan to announce today that they are partnering with pharmaceutical giant Johnson & Johnson to develop and bring to market a sophisticated, noninvasive test that can detect tiny traces of cancer cells in a blood sample. The partnership — a five-year, roughly $30 million deal — is aimed at refining and commercializing a next-generation test that could allow physicians to better target cancer-treatment regimens and monitor patients’ responses to drugs.
